key: cord-0948872-1vjhozx8 authors: Dowling, David J.; Levy, Ofer title: A Precision Adjuvant Approach to Enhance SARS-CoV-2 Vaccines Optimized for Immunologically Distinct Vulnerable Populations date: 2022-05-04 journal: Clin Infect Dis DOI: 10.1093/cid/ciac342 sha: f96c24af42657ecdb8164e9e7c6429d4de6dd1f5 doc_id: 948872 cord_uid: 1vjhozx8 The SARS-CoV-2 pandemic has caused significant mortality, especially among older adults whose distinct immune system reflects immunosenescence. Multiple SARS-CoV-2 vaccines have received emergency use authorization and or approval from the U.S. Food and Drug Administration, and throughout the world. However, their deployment has heighted significant limitations, such by age-dependent immunogenicity, requirements for multiple vaccine doses, refrigeration infrastructure that is not universally available, as well as waning immunity. Thus, there was, and continues to be a need for continued innovation during the pandemic given the desire for dose-sparing, formulations stable at more readily achievable temperatures, need for robust immunogenicity in vulnerable populations and development of safe and effective pediatric vaccines. In this context, optimal SARS-CoV-2 vaccines may ultimately rely on inclusion of adjuvants as they can potentially enhance protection of vulnerable populations and provide dose-sparing effects enabling single shot protection. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) driven coronavirus 2 disease 2019 (COVID-19) pandemic has caused significant mortality and morbidity, especially 3 among the immunologically distinct older adults (i.e., those > 65 years of age), and those with 4 chronic disease. Traditional vaccine development has largely been empirical and disregarded 5 distinct immunity in vulnerable populations. Emergency use authorization (EUA) and licensure 6 of mRNA and viral vector-based coronavirus vaccines is a major milestone in meeting the 7 challenge of the SARS-CoV-2 vaccines pandemic (1, 2). While these mRNA vaccines appear 8 safe and show 85~95% efficacy (3-6), limitations include 1) need for storage in costly freezer 9 systems that do not consistently exist in rural and/or low-and middle-income regions of the 10 world; 2) need for two dose series which is both costly and logistically challenging; and 3) 11 uncertainty regarding durability of protection, especially among the elderly who have 12 demonstrated more rapid decline of antibody (Ab) titers (6). Thus, while the newly authorized 13 mRNA vaccines are an important breakthrough, substantial vaccinology remains to be done in 14 optimizing coronavirus vaccines . 15 Vaccines have been traditionally developed with high reliance on poorly predictive 16 animal models in pre-clinical testing and a presumption that they will demonstrate equivalent 17 immunogenicity and protection in all individuals (7) . Indeed, adjuvants engage the innate 18 immune system which is hyper-variable between species (8) . Accordingly, until recently vaccine 19 discovery and development has disregarded species and age-specificity and has not tailored 20 vaccine activity to vulnerable populations such as the young, elderly and/or 21 immunocompromised (9) . Over the past few decades clinical and epidemiologic studies 22 suggests fundamental differences in immune responses to vaccines based on demographic 23 features such as age, sex, and geographic location (10). Highlighting distinct immunity with age, 24 elderly individuals and those with chronic illness such as asthma, diabetes, obesity and/or heart 25 disease, are more vulnerable to developing severe COVID-19 (11), with increasing age 26 The growing realization that vaccine immunogenicity and protection can vary by demographics 4 has prompted innovation in adjuvant discovery and development (17). In this context, a major 5 national priority, as articulated by the US NIH NIAID, is the discovery and development of 6 adjuvants that are tailored to optimally enhance immune responses in distinct and vulnerable 7 populations such as the young and elderly (31). A key approach in defining optimal adjuvants 8 for a given population with distinct immunity is human in vitro modeling. Human in vitro systems 9 include whole blood assays, monocyte-derived dendritic cell arrays and three-dimensional 10 microphysiologic systems such as the tissue construct (22, 32-36). These employ primary 11 human leukocytes and autologous plasma, a rich source of age-specific immunomodulatory 12 factors (37, 38). Multiple such in vitro studies have tested adjuvants and licensed vaccines 13 suggesting that these systems mirror and/or predict in vivo responses (32, 33, 36) . 14 Examples of age-dependent adjuvant discovery using human in vitro modeling include 15 As the pandemic unfolded, results accumulated indicating the potential value of 8 adjuvants to enhance immunogenicity of SARS-CoV-2 vaccines. Alum enhanced total IgG 9 responses to purified inactivated SARS-CoV-2 virus vaccine candidate SARS-CoV-2-specific 10 NAbs in mice, rats, and nonhuman primates (44). Aluminum-based adjuvants also enabled high 11 titers of NAbs to the S protein of SARS-CoV-2 (45), but were most effective when used in 12 combination with other PRR agonist adjuvants, especially in designing vaccines for vulnerable 13 populations with distinct immunity such as the young and elderly (32, 46) . As compared to CD4 + T-cell responses that were T helper (Th)1-biased (50). These examples suggested that 2 adjuvants may enhance effectiveness of SARS-CoV-2 vaccines. However, the growing pipeline 3 of candidate adjuvants had yet to be systematically compared in the context of SARS-CoV-2 4 vaccines. 5 In the context of the current pandemic, the rationale for identifying optimal adjuvantation 7 systems for a precision elderly SARS-CoV-2 vaccine is four-fold, as adjuvants may: 1) broaden 8 an immune response to enhance protection, 2) enable robust vaccine immunogenicity in a 9 vulnerable population with distinct and relatively weak immunity, 3) have dose-sparing effects 10 which may be crucial from a pharmaco-economic standpoint to scaling a SARS-CoV-2 vaccine 11 as 100s of millions to billions of vaccine doses may be required, and 4) increase durability of an 12 immune response, potentially enabling single dose long-term protection. As such, among the 13 priorities in the field is the generation of a toolbox of adjuvants that: a) have a well-defined 14 mechanisms of action, b) are applicable to old and/or new vaccines against diverse pathogens, 15 c) can be used in combination to produce uniquely beneficial safe and effective vaccines, and d) 16 include agents that can, alone or in combination, induce the desired protective immune profiles 17 in vulnerable populations, such as infants, elders and/or those with chronic illness (31). 18 In January 2020 and supported by NIH/NIAID's Adjuvant Discovery and Development 19 Program, our PVP team initiated an effort to discover and develop adjuvant systems to enhance 20 optimal SARS-CoV-2 vaccine immunogenicity in those most vulnerable to severe COVID-i.e., 21 older adults (those > 65 years of age). With respect to identifying optimal adjuvants to help 22 address the current coronavirus pandemic, innovative approaches we choose to undertake, 23 included a broad adjuvant discovery pipeline and, use of age-specific animal models as well as 24 human in vitro modeling of vulnerable populations innate and adaptive immune response (51). 25 These approaches are designed to provide more precise and accurate go/no go decision points 26 optimally effective for the most vulnerable, adjuvants were screened for in vitro activity towards 3 human elderly leukocytes in order to identify leads for formulation together with an optimized 4 CoV antigen. 5 Specifically, we de-risked 3 adjuvanted formulations that were shown to effectively 6 protect mice from mouse-adapted SARS-CoV-2. Firstly, we undertook a study aimed to 7 evaluate an optimal adjuvant formulation to enhance immunogenicity and efficacy of RBD- approach to develop a practical, thermostable, scalable, effective, and affordable vaccine that 20 may be effective across multiple age groups and could potentially incorporate multiple RBD 21 proteins to achieve cross-strain protection (52). Indeed, this approach represents the discovery 22 Soluble mannans were shown to be "immunosilent" in the periphery but elicited a potent pro-7 inflammatory response in the draining lymph node (dLN). By modulating the physical form of 8 mannans, we developed a formulation that targets both the periphery and the dLN. When 9 combined with viral glycoprotein antigens, this mannan formulation broadens epitope 10 recognition, elicits potent antigen-specific neutralizing antibodies, and confers protection against 11 viral infections of the lung (55). 12 The potential of a third adjuvated formulation was noted with respect to RBD- OL is also a named inventor on a patent for an in vitro system to model human immune 10 responses to adjuvants and vaccines. sub-optimal vaccine efficacy outcomes, normally attributed to an overreliance on non-human 10 species-models and underappreciated value of incorporating age-specificity readout into the 11 preclinical vaccine development pipeline. An alternative precision vaccine approach, aims to 12 accelerate development of optimal vaccine approaches, increasing the probably the final 13 formulations will better protect the most vulnerable by (a) defining a very broad adjuvant 14 pipeline, (b) rapidly screening adjuvants for activity towards human elderly PBMCs, and (c) 15 combining lead adjuvants with multiple SARS-CoV-2 antigens. Lead adjuvanted vaccines are 16 then advanced to age-specific animal studies and beyond. SARS-CoV-2 Vaccines: Status Report SARS-CoV-2 vaccines in development Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine 11 in Older Adults Ontogeny of early life immunity Variation matters: TLR 15 structure and species-specific pathogen recognition nonspecific") and sex-differential effects of vaccines: epidemiology, clinical trials, and 21 emerging immunologic mechanisms Factors associated with COVID-19-related death using 23 Sex-based differences in immune function and 25 responses to vaccination Effects of influenza immunization on pneumonia in the elderly Vaccines for the elderly: current use and future challenges Waning effectiveness of SARS-CoV-2 mRNA vaccines 7 in older adults: a rapid review Towards Precision Vaccines: Lessons From the Second International 9 Precision Vaccines Conference Precision Vaccine 11 Development: Cues From Natural Immunity Recent Advances in the Discovery and Delivery of TLR7/8 Agonists as 13 Toward precision adjuvants: optimizing science and 15 safety Key roles of adjuvants in modern vaccines Age-Specific Adjuvant Synergy: Dual TLR7/8 and Mincle 19 Activation of Human Newborn Dendritic Cells Enables Th1 Polarization Cellular and molecular synergy in AS01-adjuvanted vaccines results in 5 an early IFNgamma response promoting vaccine immunogenicity Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19 SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen 10 preparedness Introduction of Two Prolines and Removal of the Polybasic Cleavage 12 Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the 13 Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein 15 Nanoparticle Vaccine The sixth revolution in pediatric 17 vaccinology: immunoengineering and delivery systems An aluminum hydroxide:CpG adjuvant enhances protection elicited by a 19 SARS-CoV-2 receptor binding domain vaccine in aged mice Sucrose fatty acid sulphate esters as novel vaccine adjuvants: 12 effect of the chemical composition Lipid nanoparticles enhance the efficacy of mRNA and protein 14 subunit vaccines by inducing robust T follicular helper cell and humoral responses mRNA booster vaccination protects extremely aged mice against the 17 SARS-CoV-2 Omicron variant Toll-like receptor 9 antagonizes antibody affinity maturation Precision Vaccine Adjuvants for Older Adults: A Scoping Review Mapping global 23 trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale 24 retrospective temporal modelling study Immunization: vital progress, unfinished agenda